Compare Novo Nordisk A/S (NVO) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares Ultra Semiconductors — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while ProShares Ultra Semiconductors trades at $89.16. The key difference: Novo Nordisk A/S pays a 3.98% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | USD | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $113.53 |
52-Week Low | $35.29 | $43.19 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.
The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
